<DOC>
	<DOCNO>NCT01048476</DOCNO>
	<brief_summary>Lutein one oxygenate carotenoid . Over past year , increase interest evaluate effect lutein optimize eye health . A large number epidemiological study support notion high intake dietary lutein strongly associate decreased relative risk AMD.Moreover , find initial observational study follow placebo-controlled intervention trial show dietary modification supplementation lutein result increase macular pigment optical density , may help improve visual function patient suffer AMD.Currently , nutritional status background information lutein zeaxanthin Chinese population lack . Little known preventive therapy benefit lutein visual function AMD population . In particular , effect visual function relatively certain dos lutein zeaxanthin unknown . Therefore , objective present study examine effect consume different dos lutein MPOD visual function AMD .</brief_summary>
	<brief_title>Effects Lutein Zeaxanthin Supplementation Age-related Macular Degeneration</brief_title>
	<detailed_description>We aim study effect mechanism lutein prevention treatment age-related macular degeneration ( AMD ) . Using cluster sample method , baseline characteristic screen perform Han nationality men woman suburban area Beijing , range age 50 to79 year . According clinical diagnosis standard AMD , AMD ( n=120 ) normal subject ( n=40 ) randomly select measure serum lutein nutritional status , evaluate relationship lutein AMD . Each subject AMD randomly assign 1 4 group : Group low lutein ( Group LL ) ; Group high lutein ( Group HL ) ; Group lutein/zeaxanthin ( Group LZ ) ; Group Placebo participate randomize , double-blind , placebo-controlled , 1 year intervention study , respectively . Macular pigment optical density , relate symptom multifocal electroretinogram ( mfERG ) measure week 0 , 24 48 , compare dynamic change response supplement baseline follow-up visit , observe time- dose-response correlation supplementation lutein , assess efficacy , dosage lutein and/or zeaxanthin supplement .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Patients nonexudative AMD ( either categories 2 , 3 4 accord AREDS criterion ; group 4 eye noadvanced AMD include ) Age 50 90 year Able understand comply requirement trial Visual acuity &gt; 0.4 Subjects must agree take nutritional supplement Currently enrol ophthalmic clinical trial Eyes concomitant macular choroidal disorder AMD indefinite sign AMD Eyes diagnosis exudative AMD active subretinal neovascularization ( SRNV ) CNV lesion require laser photocoagulation study eye Subjects significant ocular lens opacity cause vision decrease Subjects amblyopia Subjects optic nerve disease ( neuropathy , atrophy , papilledema ) , unstable glaucoma define intraocular pressure great 25 mm Hg , 3 glaucoma medication , C/D 0.8 great visual field consistent glaucoma ; history retinavitreous surgery , degenerative myopia , active posterior intraocular inflammatory disease , chronic use topical ocular steroid medication , vasoproliferative retinopathy ( AMD ) , rhegmatogenous retinal detachment , inherit macular dystrophy Subjects demand type pacemaker epilepsy Subjects uncontrolled hypertension ( define diastolic 90 great systolic 150 great ) Subjects recent history ( within previous year ) cerebral vascular disease manifest transient ischemic attack ( TIA 's ) cerebral vascular accident ( CVA 's ) Subjects history AIDS lutein supplementation within last 3 month Subjects intraocular surgery trial eye within 3 month prior enrol trial Patients unwilling adhere visit examination schedule</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>AMD</keyword>
</DOC>